Matching geography
Reports matching your search in:
 
 
US: 800.298.5699
Int'l: +1.240.747.3093
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
Region: All Regions > Europe
Category: All Categories > Life Sciences > Pharmaceuticals > Country Overviews
(260 reports matching your criteria)
 
1  2    4    6  7  8  9  10  
Netherlands Pharmaceuticals and Healthcare Report Q4 2012
8/21/2012 | published by: Business Monitor International
... waiting times and similar factors. The key to the country’s success is a healthcare system characterised by its minimal bureaucracy, improving access to services and patient empowerment. However, such factors will not translate into a ...  |  read more...
$1,175.00
Latvia Pharmaceuticals and Healthcare Report Q4 2012
8/14/2012 | published by: Business Monitor International
... overly significant impact on our growth projections over our five- and 10-year forecast periods. We have maintained our growth rate for 2012 of 4.0% in local currency terms, but we warn this is equivalent to ...  |  read more...
$1,175.00
Belarus Pharmaceuticals and Helathcare Report Q3 2012
8/8/2012 | published by: Business Monitor International
... may keep it ticking over. However,aside from some public statements about Chinese and Indian investments, which BMI regards withscepticism, foreign pharmaceutical players will stay out of Belarus until the economy reaches a newequilibrium. In addition, ...  |  read more...
$1,175.00
Greece Pharmaceuticals and Healthcare Q3 2012
7/17/2012 | published by: Business Monitor International
... our assessment of the pharmaceutical and healthcare market, as this vote was widely seen as a proxy vote of eurozone membership. Following the result, we maintain our core forecast scenario of continued austerity. Indicators that ...  |  read more...
$1,175.00
Switzerland Pharmaceuticals and Healthcare Report Q3 2012
7/10/2012 | published by: Business Monitor International
... prompt local companies to get more involved in the segment. According to data published by Swissmedic, Sandoz Pharmaceuticals, Novartis's generic medicines arm, has 556 preparations locally approved, while Teva has 345 preparations locally approved. However, ...  |  read more...
$1,175.00
Slovakia Pharmaceuticals and Healthcare Report Q3 2012
7/10/2012 | published by: Business Monitor International
... downfall of the previous government will still be in effect. Following the appointment of Zuzana Zvolenská as the new minister of health in April, there has been no sign she will significantly alter from this ...  |  read more...
$1,175.00
Serbia Pharmaceuticals and Healthcare Report Q3 2012
7/3/2012 | published by: Business Monitor International
... challenging economic situation will hamper the purchase of necessary medicines by the majority of the cash-strapped population, especially as out-of-pocket contribution to healthcare in general stands at almost 40%. We therefore envisage generic medicines gaining ...  |  read more...
$1,175.00
France Pharmaceuticals and Healthcare Report Q3 2012
6/26/2012 | published by: Business Monitor International
... the French medicines agency (Afssaps).We note that this aligns with our core view that dialogue between firms, regulators and payers will become more common as the communication of product value becomes increasingly important. Regulatory agencies ...  |  read more...
$1,175.00
Moldova Pharmaceuticals and Healthcare Report Q3 2012
6/26/2012 | published by: Business Monitor International
... leaving it exposed to external risks in Romania and the eurozone, the seemingly encouraging imports data over the last few quarters does not appear to be sustainable. Our industry growth forecast for 2012 has been ...  |  read more...
$1,175.00
Ukraine Pharmaceuticals and Healthcare Report Q3 2012
6/26/2012 | published by: Business Monitor International
... to contagion from the European Union (EU)’s economic crisis as indicated by slowing economic growth in Q112. Continued lack of investment in the healthcare system translates into a pharmaceutical market driven by out-of-pocket purchasing and ...  |  read more...
$1,175.00
Italy Pharmaceuticals and Healthcare Report Q3 2012
6/19/2012 | published by: Business Monitor International
... are delaying payments worth billions of dollars. Our bearish outlook takes into account the deteriorating state of the economy and the country's enormous public debt burden. Headline Expenditure Projections Pharmaceuticals: EUR24.90bn (US$34.63bn) in 2011 to ...  |  read more...
$1,175.00
Romania Pharmaceuticals and Healthcare Report Q3 2012
6/19/2012 | published by: Business Monitor International
... new interim government, which will be in charge until elections in November 2012, has not had a major impact on our 2012- 2013 projections for the pharmaceutical or healthcare market. We have not had to ...  |  read more...
$1,175.00
Germany Pharmaceuticals and Healthcare Report Q3 2012
6/12/2012 | published by: Business Monitor International
... prescription drugs, as well as the implementation of mandatory discounts of up to 16% on patented drugs, will weigh more heavily on overall pharmaceutical market growth. Headline Expenditure Projections Pharmaceuticals: EUR39.68bn (US$55.15bn) in 2011 to ...  |  read more...
$1,175.00
Bulgaria Pharmaceuticals and Healthcare Report Q3 2012
6/12/2012 | published by: Business Monitor International
... country, despite the short-term challenges we still believe the market is attractive and will generate high single-digit yearly growth over our five-year forecast period. Our 2012- 2013 industry forecast scenario for Bulgaria’s pharmaceutical market is ...  |  read more...
$1,175.00
Belgium Pharmaceuticals and Healthcare Report Q3 2012
6/5/2012 | published by: Business Monitor International
... fiscal austerities in regards to public spending in the face of economic difficulties, the prospects for the placement of expensive patented medicines onto the Belgian market will remain subdued over the short term at least, ...  |  read more...
$1,175.00
Slovenia Pharmaceuticals and Healthcare Report Q3 2012
6/5/2012 | published by: Business Monitor International
... measures to control public drug expenditure. The government’s methods are considerably less aggressive than those in other Central and Eastern European (CEE) markets, and are as such not expected to result in the market value ...  |  read more...
$1,175.00
Poland Pharmaceuticals and Healthcare Report Q3 2012
6/5/2012 | published by: Business Monitor International
... the public and members of the healthcare profession, and also resulted in volatility of pharmaceutical spending, we maintain our view of positive growth for 2012, projecting 1.6% year-on-year (y-o-y) expansion. Headline Expenditure Projections Pharmaceuticals: PLN33.37bn ...  |  read more...
$1,175.00
Croatia Pharmaceuticals and Healthcare Report Q3 2012
5/29/2012 | published by: Business Monitor International
... performance of Croatia’s pharmaceutical, healthcare and medical device markets is increasingly tied to the country’s challenging economic outlook. This dependence will render Croatia one of the least attractive regional markets, despite the country’s gradual convergence ...  |  read more...
$1,175.00
Estonia Pharmaceuticals and Healthcare Report Q3 2012
5/29/2012 | published by: Business Monitor International
... downward revision to our 2012 outlook, as our optimism that elevated economic growth would be maintained has diminished. Still, the country’s proximity to Western Europe and its integration into regional trade networks means imports will ...  |  read more...
$1,175.00
Hungary Pharmaceuticals and Healthcare Report Q3 2012
5/29/2012 | published by: Business Monitor International
... pharmaceutical market, which we have had for well over a year, has been reinforced by the latest version of the structural reform package Széll Kálmán Plan 2.0. We have adjusted our forecasts down further, reflecting ...  |  read more...
$1,175.00
Netherlands Pharmaceuticals and Healthcare Report Q3 2012
5/22/2012 | published by: Business Monitor International
... A further challenge facing drugmakers is cost-containment, which can only intensify as the Netherlands enters a phase of slower economic growth. Headline Expenditure Projections Pharmaceuticals: EUR6.70bn (US$9.31bn) in 2011 to EUR6.54bn (US$8.44bn) in 2012; -2.4% ...  |  read more...
$1,175.00
The Pharmaceutical Market: Poland
5/15/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  read more...
$1,085.00
The Pharmaceutical Market: Germany
5/14/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  read more...
$1,085.00
The Pharmaceutical Market: Croatia
5/14/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  read more...
$1,085.00
Latvia Pharmaceuticals and Healthcare Report Q3 2012
5/8/2012 | published by: Business Monitor International
... environment in Europe, which will not be supportive of Latvian exports and therefore economic growth. We forecast 4.3% year-on-year (y-o-y) local currency growth in 2012, with the market expected to be valued at LVL296mn (US$540mn) ...  |  read more...
$1,175.00
1  2    4    6  7  8  9  10